Abstract:While the Alzheimer's disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is commonly used to measure cognitive decline in probable Alzheimer's disease (pAD) and mild cognitive impairment (MCI) patients, rates of decline vary. We previously introduced a single index, Hypometabolic Convergence Index (HCI), to characterize the extent to which the pattern and magnitude of cerebral hypometabolism in a person's fluorodeoxyglucose-positron emission tomography (FDG-PET) image corresponds to that in pAD patients. Here, we used data from ADNI to examine the extent to which 1) a person's baseline HCI predicts cognitive decline using the ADAS-Cog, Mini-Mental State Exam (MMSE), Clinical Dementia Rating-sum of boxes (CDR-SB) and Auditory-Verbal Learning Test (AVLT-Total), and 2) the HCI could be used to enrich clinical trials for clinical decline and reduce the number of patients needed to detect a treatment's clinical effects. Baseline HCIs were computed for 120 MCI and 54 mild AD patients who had up to 24-month data. We first characterized the extent to which HCIs correlated with 12-month and 24-month clinical declines. We then estimated the sample sizes needed to detect an AD-slowing treatment's effects on ADAS-Cog before/after enrichment for those patients with HCIs greater than the predetermined threshold of 13.82 for pAD and 8.19 for MCI (Chen et al., 2011, Neuroimage) with 80% power, 0.05 type-I error and a 25% treatment effect. In pAD, HCIs correlated (p < = 0.05) with subsequent ADAS-Cog, MMSE, CDR-SB and AVLT-Total 12-month(24-month) decline (r = 0.42(0.47), -0.35(-0.55), 0.28(0.29), -0.40(-0.43), respectively). In MCI, HCI also correlated with subsequent decline at 12-month(24-month) (r = 0.33(0.32), -0.43(-0.50), 0.29(0.37), -0.17(-0.32), respectively). HCI enrichment is estimated to reduce the number of pAD patients needed per treatment arm to detect an AD-slowing treatment's effect on ADAS-Cog from 406 to 243 in a 12-month trial and from 168 to 137 in a 24-month trial. Similarly, it is estimated to reduce the number of MCI patients from 1,718 to 749 in a 12-month trial and from 926 to 374 in a 24-month trial. Baseline HCIs could be used to predict subsequent clinical declines in pAD and MCI patients and to reduce the number of patients needed to detect an AD-slowing treatment's effects in randomized clinical trials.

P1‐434: Twelve‐month Whole‐brain Atrophy Rates and Estimated Power to Detect Alzheimer‐slowing Treatment Effects in Multicenter Trials Using Iterative Principal Component Analysis: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

Whole Brain Atrophy and Sample Size Estimate Via Iterative Principal Component Analysis for Twelve-month Alzheimer's Disease Trials

Clinical and Neuroimaging Differences Between Posterior Cortical Atrophy and Typical Amnestic Alzheimer’s Disease Patients at an Early Disease Stage

Whole Brain Atrophy Based on Iterative Principal Component Analysis and MRI Techniques in the Study of Alzheimer's Disease

O1-02-06: Twelve-month Cerebral Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

An Automated Algorithm for the Computation of Brain Volume Change from Sequential MRIs Using an Iterative Principal Component Analysis and Its Evaluation for the Assessment of Whole-Brain Atrophy Rates in Patients with Probable Alzheimer's Disease.

Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease.

Twelve-month Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment Assessed Using an Empirically Pre-Defined Statistical Region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

O1-04-05: Six-month Cerebral Metabolic Declines in Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Elderly Normal Control Groups: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

IC‐P‐089: Can Three Months MRI Volumetric Parameters Help the Prediction of Progression from MCI to Alzheimer's Disease? Results from the Addneuromed Study

P2-249: Using brain 3D-MRI and 1H MRS imaging for early diagnosis of Alzheimer's disease

[IC‐P‐041]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD

Use of an FDG-PET Derived Hypometabolic Convergence Index Enrichment Strategy to Reduce Sample Sizes in Alzheimer's Disease Clinical Trials: Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Longitudinal Relationship Between Brain Atrophy Patterns, Cognitive Decline, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Explored by Orthonormal Projective Non-Negative Matrix Factorization

Impact of Different PET Image Quantification Methods, Regions-of-interest and Risk Factors on the Power to Detect a Slowing in Beta-Amyloid Deposition in Presymptomatic Alzheimer's Disease Trials

Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy

IC‐P2‐074: Differentiating Amnestic MCI Converting to Probable AD from Stable Amnestic MCI Using FDG‐PET and an AD‐related Hypometabolism Overlap Index

SAMPLE SIZES FOR 24-MONTH ALZHEIMER’S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS

P1‐312: Differentiating Amnestic Mild Cognitive Impairment Converting to Probable Alzheimer's Disease from Stable Amnestic Mild Cognitive Impairment Using FDG‐PET and an Alzheimer's Disease‐related Hypometabolism Overlap Index